市場調查報告書
商品編碼
1272774
2023-2030 年胸腺癌全球市場Global Thymus Cancer Market - 2023-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
胸腺癌的全球市場預計將在 2022 年達到 4.614 億美元,預計到 2030 年將達到 7.025 億美元。 胸腺癌市場預計在預測期內(2023-2030 年)的複合年增長率為 5.5%。 主要參與者正在採取合作夥伴關係、合併、收購、產品批准和區域擴張等戰略,以在胸腺癌市場中脫穎而出,成為強大的競爭對手。
例如,2023 年 1 月 17 日,默克公司的抗 PD-1 藥物 KEYTRUDA 被手術用於患有 IB 期(T2a 4 cm)、II 期或 IIIA 期非小細胞肺癌的成年患者。美國食品和藥物管理局 (FDA) 將其作為單藥作為切除和鉑類化療 (NSCLC) 後的輔助治療。
胸腺癌是一種惡性(癌)細胞在胸腺中形成的疾病。 胸腺瘤、胸腺癌和胸腺神經內分泌腫瘤 (TNET),也稱為胸腺上皮腫瘤 (TET),是一種在胸腺排列的細胞中形成的罕見癌症。 市場的逐步發展、胸腺癌病例數量的增加以及研究活動的增加是預計在預測期內推動全球胸腺癌市場增長的一些因素。
胸腺癌患病率的增加預計將推動市場增長。 例如,根據英國癌症研究中心的數據,胸腺癌很罕見。 英國每年約有 345 人被診斷出患有胸腺癌。 這包括胸腺瘤和胸腺癌。
但是,確切的數字是未知的,並且可能高於計算機斷層掃描可以檢測到的估計數字。 胸腺瘤和胸腺癌通常發生在 40 至 60 歲的人群中,但它們幾乎可以發生在任何年齡段。 因此,老年人口的增加可能會導致胸腺癌的流行。
有幾種方法可以開發胸腺癌的新療法,這將為未來幾年的胸腺癌市場提供有利可圖的增長機會。 例如,研究人員正在探索使用免疫療法來利用免疫系統的力量來靶向和摧毀癌細胞。 正在考慮其他方法,例如專注於參與胸腺癌發生和進展的特定分子途徑的靶向治療。
對 COVID-19 的分析包括 COVID 之前、COVID 和 COVID 之後的情景、價格動態(與 COVID 之前的情景相比,大流行期間和之後的價格變化)、供需範圍(需求和供應的變化由於貿易限制、封鎖和後續問題);行動)也有解釋。
由於該地區缺乏主要市場參與者且該疾病的總體患病率較低,預計俄烏衝突對全球胸腺癌市場的影響可以忽略不計。 然而,這場戰爭預計對全球胸腺癌市場的影響最小,削弱了在該地區進行的研究活動。
醫療保健行業並非完全不受衰退影響。 但這個行業,就其本質而言,比其他行業應對得更好。 經濟衰退導致研究投資下降,這對過去幾年的市場增長產生了負面影響。
AI在不同癌症中的應用不成比例,對縱隔腫瘤的關注不夠,未來發展空間和潛力較大。 例如,汕頭市中心醫院放射科的研究人員得出結論,基於機器學習的 CT 圖像在預測調查的不同組織學分類以及浸潤水平方面具有重要價值。 因此,人工智能有望在未來幾年對全球胸腺癌市場產生積極影響。
了解有關此報告的更多信息 - 索取樣本
The global thymus cancer market reached US$ 461.4 million in 2022 and is projected to witness to reach up to US$ 702.5 million by 2030. The thymus cancer market is expected to exhibit a CAGR of 5.5% during the forecast period (2023-2030). The key players are adopting strategies such as partnerships, mergers, acquisitions, product approvals, and regional expansion to stand out as strong competitors in the thymus cancer market.
For instance, on January 17, 2023, for adult patients with stage IB (T2a 4 cm), stage II, or stage IIIA non-small cell lung cancer, Merck's anti-PD-1 medication, KEYTRUDA, was approved by the U.S. Food and Drug Administration (FDA) as a single agent for adjuvant treatment after surgical resection and platinum-based chemotherapy (NSCLC).
Thymus cancer is a disease in which malignant (cancer) cells form in the thymus. Thymoma, Thymic Carcinoma, and Thymic Neuroendocrine Tumor (TNET) also called thymic epithelial tumors (TETs), are types of rare cancers that can form in the cells covering the thymus's outside surface. The increasing market developments, growing cases of thymus cancer, and increasing research activities are some of the factors that are expected to drive the global thymus cancer market growth over the forecast period.
The increasing prevalence of thymus cancer is expected to boost the market growth. For instance, according to Cancer Research UK, thymus gland cancer is rare. In the U.K., around 345 people are diagnosed with thymus cancer each year. This includes thymoma and thymic carcinoma.
However, the exact number is not known and may be higher than the estimated number that can be detected using computed tomography scans. Thymoma and thymic carcinoma usually occurs in people between the ages of 40 and 60 but can occur at almost any age. Thus, the rising older population is likely to contribute to thymus cancer prevalence.
There are several approaches that could be pursued to develop new treatments for thymus cancer presenting the thymus cancer market with lucrative growth opportunities in the forthcoming years. For example, researchers are exploring the use of immunotherapies, which harness the power of the immune system to target and destroy cancer cells. Other potential approaches include targeted therapies that focus on specific molecular pathways involved in the development and progression of thymus cancer.
The COVID-19 analysis includes Pre-COVID Scenario, COVID Scenario, and Post-COVID Scenario along with pricing dynamics (including pricing change during and post-pandemic comparing it to pre-COVID scenarios), demand-supply spectrum (shift in demand and supply owing to trading restrictions, lockdown, and subsequent issues), government initiatives (initiatives to revive market, sector or industry by government bodies) and manufacturers strategic initiatives (what manufacturers did to mitigate the COVID issues will be covered here).
The Russia-Ukraine war is estimated to have nearly negligible impact on the global thymus cancer market, owing to the absence of key market players in this region and the overall low prevalence of the condition. Still, the war has slowed the research activities carried out in this region, which is expected to have the slightest impact on the global thymus cancer market.
The healthcare industry is not completely immune to recession, as healthcare institutions thought firings and employing freezes during past financial downturns. That stated, the industry does cope finer than other sectors because of its essential nature. The recession has led to a decrease in research investments which has negatively impacted the market growth in the past few years.
The application of AI in different cancers is disproportionate, and enough attention has not been paid to mediastinal tumors, showing a huge gap and potential for future development. For instance, the researchers from the Department of Radiology, Shantou Central Hospital concluded that the machine learning-based CT image had significant values in the prediction of different histological classifications and even invasion levels from their investigation. Thus, artificial intelligence is estimated to positively impact the global thymus cancer market in the upcoming years.
For more details on this report - Request for Sample
The global thymus cancer market is segmented based on cancer type, treatment, end users, and region.
Surgical removal of the tumor is the primary form of treatment for thymus cancer. An incision is made in the center of the chest and the sternum (chest bone) is split, allowing the surgeon full access to the thymus gland. Depending on the extent of cancer, the tumor is removed and the entire thymus gland is removed (a procedure called a thymectomy), and/or parts of nearby organs where the tumor has spread. Moreover, the rising clinical research activities are boosting the surgery treatment segment growth in the forecast period.
For instance, in 2022, according to ClinicalTrials.com., Shanghai Zhongshan Hospital completed an interventional study comparing the safety and perioperative outcomes of the subxiphoid approach versus lateral intercostal approach thoracoscopic thymectomy for Masaoka-Koga I-II Thymoma.
The increasing initiatives and funding in the fight against thymus cancer in this region are boosting the European thymus cancer market growth and are estimated to hold around 26.2% of the global thymus cancer market by 2030. For instance, ThymicUK, a registered charity established by patients with thymic cancers, their carers, and families and friends, raised slightly more than £10,000 from fundraisers and grants to support those impacted by rare thymic cancers.
The major global players in the market include Merck & Co., Inc., Viatris Inc., F. Hoffmann-La Roche Ltd, Elekta AB, Asensus Surgical US, Inc., Pfizer Inc., Getwell Pharmaceuticals, Bristol-Myers Squibb Company, Intuitive Surgical and Varian Medical Systems, Inc. (Siemens Healthineers AG) among others.
The global thymus cancer market report would provide approximately 53 tables, 54 figures, and 195 Pages.
LIST NOT EXHAUSTIVE